Log in with your email address username.


[Comment] Postmenopausal breast cancer: a best endocrine strategy?

Postmenopausal, oestrogen receptor (ER)-positive breast cancers account for the majority of the 1·7 million breast cancers diagnosed annually worldwide. Adjuvant endocrine therapy dramatically improves survival among such patients, making it vital to understand the best treatment strategies. For decades, the Early Breast Cancer Trialists’ Collaborative Group meta-analyses have informed clinical practice in early-stage breast cancer, and the present report1 in The Lancet on over 30 000 women treated with adjuvant tamoxifen, aromatase inhibitors, or a sequence of those agents continues that tradition.